Format

Send to

Choose Destination
J Antimicrob Chemother. 2016 Mar;71(3):821-9. doi: 10.1093/jac/dkv411. Epub 2015 Dec 17.

A randomized, double-blind, Phase 2 study to evaluate subjective and objective outcomes in patients with acute bacterial skin and skin structure infections treated with delafloxacin, linezolid or vancomycin.

Author information

1
Columbus Regional Research Institute, 800 Talbotton Road, Columbus, GA 31904, USA.
2
Artemis Institute for Clinical Research, 770 Washington St., San Diego, CA 92103, USA.
3
Melinta Therapeutics, 300 George Street, New Haven, CT 06511, USA.
4
H2O Clinical, 224 Schilling Circle, Hunt Valley, MD 21031, USA.
5
Melinta Therapeutics, 300 George Street, New Haven, CT 06511, USA scammarata@melinta.com.
6
Mercury Street Medical Group, PLLC, 300 West Mercury Street, Butte, MT 59701, USA.

Abstract

OBJECTIVES:

Delafloxacin is an investigational anionic fluoroquinolone being developed to treat infections caused by Gram-positive and -negative organisms. This clinical trial evaluated the efficacy and safety of delafloxacin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs).

METHODS:

In a double-blind, Phase 2 trial, 256 patients were randomized (1 : 1 : 1) to 300 mg of delafloxacin, 600 mg of linezolid or 15 mg/kg vancomycin (actual body weight), each administered intravenously twice daily for 5-14 days. Randomization was stratified by infection category. The primary endpoint was the investigator's assessment of cure, defined as complete resolution of baseline signs and symptoms at follow-up. Secondary endpoints included reductions in the total areas of erythema and induration and assessments of bacterial eradication. This trial has been registered at ClinicalTrials.gov under registration number NCT01283581.

RESULTS:

Cure rates were significantly greater with delafloxacin versus vancomycin (mean difference: -16.3%; 95% CI, -30.3% to -2.3%; P = 0.031); differences were significant for obese patients (BMI ≥30 kg/m(2); mean difference: -30.0%; 95% CI, -50.7% to -9.3%; P = 0.009), but not for non-obese patients. Cure rates with delafloxacin and linezolid were similar. Using digital measurement, the percentage decrease in total erythema area was significantly greater with delafloxacin versus vancomycin at follow-up (-96.4% versus -84.5%; P = 0.028). There were no differences in bacterial eradication among the treatment groups. The most frequently reported treatment-emergent adverse events were nausea, diarrhoea and vomiting.

CONCLUSIONS:

These data show that delafloxacin is effective in the treatment of ABSSSIs and is well tolerated.

PMID:
26679243
PMCID:
PMC4743703
DOI:
10.1093/jac/dkv411
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center